Shane Nanayakkara

Shane Nanayakkara

Auto-generated profile, based on publicly available information

Shane Nanayakkara

Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2019 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
FTFernando Telles
Fernando Telles
SNShane Nanayakkara
Shane Nanayakkara
SEShona Evans
Shona Evans
HPHitesh C. Patel
Hitesh C. Patel
JMJustin A. Mariani
Justin A. Mariani
DKDavid M. Kaye
David M. Kaye

6 July 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
ABAnna Beale
Anna Beale
JOJoanne A. O’donnell
Joanne A. O’donnell
MNMichael E. Nakai
Michael E. Nakai
SNShane Nanayakkara
Shane Nanayakkara
DVDonna Vizi
Donna Vizi
DKDavid Kaye
David Kaye
Background: Risk factors for heart failure with preserved ejection fraction (HFpEF) include hypertension, age, sex, and obesity. Emerging evidence suggests that the gut microbiota independently contributes to each one of these risk factors, potentially mediated via gut microbial‐derived metabolites such as short‐chain fatty acids. In this study, we determined whether the gut microbiota were associated with HFpEF and its risk factors. Methods and Results: We recruited 26 patients with HFpEF and 67 control participants from 2 independent communities. Patients with HFpEF were diagnosed by exercise right heart catheterization. We assessed the gut microbiome by bacterial 16S rRNA sequencing and food intake by the food frequency questionnaire. There was a significant difference in α‐diversity (eg, number of microbes) and β‐diversity (eg, type and abundance of microbes) between both cohorts of controls and patients with HFpEF ( P =0.001). We did not find an association between β‐diversity and specific demographic or hemodynamic parameters or risk factors for HFpEF. The Firmicutes to Bacteroidetes ratio, a commonly used marker of gut dysbiosis, was lower, but not significantly so ( P =0.093), in the patients with HFpEF. Compared with controls, the gut microbiome of patients with HFpEF was depleted of bacteria that are short‐chain fatty acid producers. Consistent with this, participants with HFpEF consumed less dietary fiber (17.6±7.7 versus 23.2±8.8 g/day; P =0.016). Conclusions: We demonstrate key changes in the gut microbiota in patients with HFpEF, including the depletion of bacteria that generate metabolites known to be important for cardiovascular homeostasis. Further studies are required to validate the role of these gut microbiota and metabolites in the pathophysiology of HFpEF.

1 March 2019 in JACC: Heart Failure
Verified
Journal Article
Closed access
ABAnna L. Beale
Anna L. Beale
SNShane Nanayakkara
Shane Nanayakkara
LSLouise Segan
Louise Segan
JMJustin A. Mariani
Justin A. Mariani
MMMicha T. Maeder
Micha T. Maeder
DKDavid Kaye
David Kaye

1 March 2023 in JACC: Heart Failure
Verified
Journal Article
Closed access
DCDavid Chieng
David Chieng
HSHariharan Sugumar
Hariharan Sugumar
LSLouise Segan
Louise Segan
CTCaleb Tan
Caleb Tan
DVDonna Vizi
Donna Vizi
LLLiang-Han Ling
Liang-Han Ling

30 November 2018 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
SNShane Nanayakkara
Shane Nanayakkara
SFSam Fogarty
Sam Fogarty
MTMichael Tremeer
Michael Tremeer
KRKelvin Ross
Kelvin Ross
BRBrent Richards
Brent Richards
DKDavid Kaye
David Kaye
Resuscitated cardiac arrest is associated with high mortality; however, the ability to estimate risk of adverse outcomes using existing illness severity scores is limited. Using in-hospital data available within the first 24 hours of admission, we aimed to develop more accurate models of risk prediction using both logistic regression (LR) and machine learning (ML) techniques, with a combination of demographic, physiologic, and biochemical information. Patient-level data were extracted from the Australian and New Zealand Intensive Care Society (ANZICS) Adult Patient Database for patients who had experienced a cardiac arrest within 24 hours prior to admission to an intensive care unit (ICU) during the period January 2006 to December 2016. The primary outcome was in-hospital mortality. The models were trained and tested on a dataset (split 90:10) including age, lowest and highest physiologic variables during the first 24 hours, and key past medical history. LR and 5 ML approaches (gradient boosting machine [GBM], support vector classifier [SVC], random forest [RF], artificial neural network [ANN], and an ensemble) were compared to the APACHE III and Australian and New Zealand Risk of Death (ANZROD) predictions. In all, 39,566 patients from 186 ICUs were analysed. Mean (±SD) age was 61 ± 17 years; 65% were male. Overall in-hospital mortality was 45.5%. Models were evaluated in the test set. The APACHE III and ANZROD scores demonstrated good discrimination (area under the receiver operating characteristic curve [AUROC] = 0.80 [95% CI 0.79–0.82] and 0.81 [95% CI 0.8–0.82], respectively) and modest calibration (Brier score 0.19 for both), which was slightly improved by LR (AUROC = 0.82 [95% CI 0.81–0.83], DeLong test, p < 0.001). Discrimination was significantly improved using ML models (ensemble and GBM AUROCs = 0.87 [95% CI 0.86–0.88], DeLong test, p < 0.001), with an improvement in performance (Brier score reduction of 22%). Explainability models were created to assist in identifying the physiologic features that most contributed to an individual patient’s survival. Key limitations include the absence of pre-hospital data and absence of external validation. ML approaches significantly enhance predictive discrimination for mortality following cardiac arrest compared to existing illness severity scores and LR, without the use of pre-hospital data. The discriminative ability of these ML models requires validation in external cohorts to establish generalisability.

23 June 2023 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
LSLouise Segan
Louise Segan
RCRodrigo Canovas
Rodrigo Canovas
SNShane Nanayakkara
Shane Nanayakkara
DCDavid Chieng
David Chieng
SPSandeep Prabhu
Sandeep Prabhu
PKPeter M Kistler
Peter M Kistler
Lifestyle risk factors are a modifiable target in atrial fibrillation (AF) management. The relative contribution of individual lifestyle risk factors to AF development has not been described. Development and validation of an AF lifestyle risk score to identify individuals at risk of AF in the general population are the aims of the study. The UK Biobank (UKB) and Framingham Heart Study (FHS) are large prospective cohorts with outcomes measured >10 years. Incident AF was based on International Classification of Diseases version 10 coding. Prior AF was excluded. Cox proportional hazards regression identified independent AF predictors, which were evaluated in a multivariable model. A weighted score was developed in the UKB and externally validated in the FHS. Kaplan–Meier estimates ascertained the risk of AF development. Among 314 280 UKB participants, AF incidence was 5.7%, with median time to AF 7.6 years (interquartile range 4.5–10.2). Hypertension, age, body mass index, male sex, sleep apnoea, smoking, and alcohol were predictive variables (all P < 0.001); physical inactivity [hazard ratio (HR) 1.01, 95% confidence interval (CI) 0.96–1.05, P = 0.80] and diabetes (HR 1.03, 95% CI 0.97–1.09, P = 0·38) were not significant. The HARMS2-AF score had similar predictive performance [area under the curve (AUC) 0.782] to the unweighted model (AUC 0.802) in the UKB. External validation in the FHS (AF incidence 6.0% of 7171 participants) demonstrated an AUC of 0.757 (95% CI 0.735–0.779). A higher HARMS2-AF score (≥5 points) was associated with a heightened AF risk (score 5–9: HR 12.79; score 10–14: HR 38.70). The HARMS2-AF risk model outperformed the Framingham-AF (AUC 0.568) and ARIC (AUC 0.713) risk models (both P < 0.001) and was comparable to the CHARGE-AF risk score (AUC 0.754, P = 0.73). The HARMS2-AF score is a novel lifestyle risk score which may help identify individuals at risk of AF in the general community and assist population screening. HARMS2-AF lifestyle risk score (left). Performance of the HARMS2-AF risk score in predicting the 5- and 10-year risk of AF development among the UKB and FHS (top right). Kaplan–Meier estimate of AF risk according to risk tertiles in the UKB (bottom right). AF, atrial fibrillation; AUC, area under the curve; BMI, body mass index; CI, confidence interval; FHS, Framingham Heart Study; HR, hazard ratio; UKB, UK Biobank.